Outlook Therapeutics (OTLK) Consolidated Net Income: 2015-2020
Historic Consolidated Net Income for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$9.9 million.
- Outlook Therapeutics' Consolidated Net Income rose 1.73% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$38.3 million, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- According to the latest figures from Q3 2020, Outlook Therapeutics' Consolidated Net Income is -$9.9 million, which was down 229.09% from -$3.0 million recorded in Q2 2020.
- In the past 5 years, Outlook Therapeutics' Consolidated Net Income ranged from a high of -$1.9 million in Q4 2017 and a low of -$22.3 million during Q2 2016.
- Its 3-year average for Consolidated Net Income is -$9.2 million, with a median of -$9.7 million in 2018.
- In the last 5 years, Outlook Therapeutics' Consolidated Net Income skyrocketed by 89.94% in 2017 and then plummeted by 407.26% in 2018.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Consolidated Net Income stood at -$19.1 million in 2016, then skyrocketed by 89.94% to -$1.9 million in 2017, then tumbled by 407.26% to -$9.7 million in 2018, then rose by 9.86% to -$8.8 million in 2019, then increased by 1.73% to -$9.9 million in 2020.
- Its Consolidated Net Income was -$9.9 million in Q3 2020, compared to -$3.0 million in Q2 2020 and -$16.6 million in Q1 2020.